Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Acquisition expands Merck’s growing hematology portfolio
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
Subscribe To Our Newsletter & Stay Updated
